Bio-Techne Corporation reported flat revenue of $1.2 billion for fiscal year 2026, with a 3% organic revenue increase in Q4. GAAP EPS rose to $1.16 for the full year from $0.46 last year, while adjusted EPS slightly increased to $1.93. The company highlighted improved operating margins and profitability initiatives. Bio-Techne also confirmed its pending acquisition by Merck KGaA for $73 per share, valuing the deal at approximately $11.3 billion, signaling strategic growth opportunities ahead.
Bio-Techne Corporation has corrected its previously announced shareholder record date for its quarterly dividend to August 24, 2026, instead of August 17, 2026. The company will pay a dividend of $0.08 per share on August 28, 2026, to shareholders re...
Bio-Techne Corporation announced a quarterly dividend of $0.08 per share for the quarter ended June 30, 2026. The dividend will be paid on August 28, 2026, to shareholders of record as of August 17, 2026. The company, a global life sciences firm with...
